Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 77,862
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12577232 | N-heterocycle substituted tryptamine derivatives and methods of using | 🖼🧊📄§ | 2026-03-17 | 2045-05-29 | 0 | 31 |
| 12577247 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | 🖼🧊📄§ | 2026-03-17 | 2042-01-07 | 0 | 31 |
| 12577249 | GCN2 and perk kinase inhibitors and methods of use thereof | 🖼🧊📄§ | 2026-03-17 | 2042-12-02 | 0 | 31 |
| 12577279 | Influenza virus vaccines and uses thereof | 🖼🧊📄§ | 2026-03-17 | 2040-10-15 | 0 | 31 |
| 12577282 | Galectin-1/ galectin-3 chimeras and multivalent proteins | 🖼🧊📄§ | 2026-03-17 | 2040-02-28 | 0 | 31 |
| 12577290 | FasL expression and FasR gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death | 🖼🧊📄§ | 2026-03-17 | 2042-03-04 | 0 | 31 |
| 12577286 | T cell receptors which recognize mutated EGFR | 🖼🧊📄§ | 2026-03-17 | 2039-05-01 | 0 | 31 |
| 12577288 | Methods and compositions relating to chimeric antigen receptors | 🖼🧊📄§ | 2026-03-17 | 2042-11-08 | 0 | 31 |
| 12577289 | Surrogate co-receptors for t cells and methods of use | 🖼🧊📄§ | 2026-03-17 | 2041-09-20 | 0 | 31 |
| 12577291 | Means and methods for treating and diagnosing fibrosis or fibrosis-associated diseases | 🖼🧊📄§ | 2026-03-17 | 2042-11-22 | 0 | 31 |
| 12577294 | Antibody-mediated transduction of heat shock proteins into living cells | 🖼🧊📄§ | 2026-03-17 | 2040-05-27 | 0 | 31 |
| 12577296 | Compositions and methods for growth factor modulation | 🖼🧊📄§ | 2026-03-17 | 2040-01-07 | 0 | 31 |
| 12577297 | Anti-IL-23p19 antibody formulations | 🖼🧊📄§ | 2026-03-17 | 2040-09-08 | 0 | 31 |
| 12577299 | Anti-IL-27 antibodies and uses thereof | 🖼🧊📄§ | 2026-03-17 | 2042-05-06 | 0 | 31 |
| 12577300 | Neutralizing antibodies to human endothelin | 🖼🧊📄§ | 2026-03-17 | 2041-12-20 | 0 | 31 |
| 12577302 | Anti-TIM-3 antibodies and compositions | 🖼🧊📄§ | 2026-03-17 | 2042-05-11 | 0 | 31 |
| 12577308 | Anti-E-selectin antibodies, compositions and methods of use | 🖼🧊📄§ | 2026-03-17 | 2043-02-27 | 0 | 31 |
| 12577303 | SIRPα-targeting antibody or antigen binding fragment thereof, and preparation and application thereof | 🖼🧊📄§ | 2026-03-17 | 2041-03-17 | 0 | 31 |
| 12577304 | Anti-CD3 antibodies with low binding affinity | 🖼🧊📄§ | 2026-03-17 | 2041-03-19 | 0 | 31 |
| 12577315 | Antibodies to CD40 with enhanced agonist activity | 🖼🧊📄§ | 2026-03-17 | 2043-07-31 | 0 | 31 |
| 12577309 | Anti-CSF1R molecules and use thereof | 🖼🧊📄§ | 2026-03-17 | 2040-12-23 | 0 | 31 |
| 12577311 | Chimeric antigen receptor factories and methods of use thereof | 🖼🧊📄§ | 2026-03-17 | 2039-12-02 | 0 | 31 |
| 12577318 | Humanized anti-CA IX antibodies and methods of their use | 🖼🧊📄§ | 2026-03-17 | 2039-11-05 | 0 | 31 |
| 12577323 | Compositions and conjugates comprising an interleukin and polypeptides that specifically bind TGF-beta | 🖼🧊📄§ | 2026-03-17 | 2036-06-08 | 0 | 31 |
| 12577327 | Mixed binding domains | 🖼🧊📄§ | 2026-03-17 | 2039-12-27 | 0 | 31 |
| 12576124 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | 🖼🧊📄§ | 2026-03-17 | 2040-02-18 | 0 | 31 |
| 12576125 | Desmopressin oral compositions | 🖼🧊📄§ | 2026-03-17 | 2045-05-27 | 0 | 31 |
| 12576120 | Antiproliferative effect of agarophyton chilensis extract in prostate cancer | 🖼🧊📄§ | 2026-03-17 | 2039-06-28 | 0 | 31 |
| 12576122 | Combination therapy for cancer | 🖼🧊📄§ | 2026-03-17 | 2039-02-11 | 0 | 31 |
| 12576126 | Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof | 🖼🧊📄§ | 2026-03-17 | 2040-09-04 | 0 | 31 |
| 12576130 | Dominant negative SARM1 molecules comprising a substitution at position 189, 190, 193, 194, 570 and/or 685 of SARM1 | 🖼🧊📄§ | 2026-03-17 | 2038-10-18 | 0 | 31 |
| 12576132 | Isthmin 1 for treatment of lung inflammation | 🖼🧊📄§ | 2026-03-17 | 2040-03-06 | 0 | 31 |
| 12576127 | Fibroblast binding agents and use thereof | 🖼🧊📄§ | 2026-03-17 | 2044-01-02 | 0 | 31 |
| 12576134 | Antiviral lectin and uses thereof | 🖼🧊📄§ | 2026-03-17 | 2039-09-06 | 0 | 31 |
| 12576137 | Collagen hydrolysate comprising GPCR ligand peptide | 🖼🧊📄§ | 2026-03-17 | 2042-11-23 | 0 | 31 |
| 12576136 | Insulin derivative | 🖼🧊📄§ | 2026-03-17 | 2040-12-29 | 0 | 31 |
| 12576135 | Compositions and methods for anti-TnMUC1 gold CAR t-cells | 🖼🧊📄§ | 2026-03-17 | 2042-09-21 | 0 | 31 |
| 12576145 | Crimean-Congo hemorrhagic fever virus M-segment nucleic acid vaccine and methods of use and production | 🖼🧊📄§ | 2026-03-17 | 2041-09-30 | 0 | 31 |
| 12576146 | Method for producing reassortant influenza viruses | 🖼🧊📄§ | 2026-03-17 | 2040-11-18 | 0 | 31 |
| 12576144 | Vaccines against Powassan virus, and methods of using same | 🖼🧊📄§ | 2026-03-17 | 2039-12-20 | 0 | 31 |
| 12576142 | Universal donor cells and related methods | 🖼🧊📄§ | 2026-03-17 | 2043-09-21 | 0 | 31 |
| 12576147 | Recombinant proteins with CD40 activating properties | 🖼🧊📄§ | 2026-03-17 | 2040-03-26 | 0 | 31 |
| 12576150 | CD4+ T cells expressing IL-10 and chimeric antigen receptors and uses thereof | 🖼🧊📄§ | 2026-03-17 | 2045-02-26 | 0 | 31 |
| 12576148 | Engineered immune effector cells for cancer immunotherapy that are resistant to fratricide by virtue of having genetically modified surface antigens | 🖼🧊📄§ | 2026-03-17 | 2044-01-31 | 0 | 31 |
| 12576151 | Fratricide resistant modified immune cells and methods of using the same | 🖼🧊📄§ | 2026-03-17 | 2041-09-24 | 0 | 31 |
| 12576155 | Senolytic and antiinflammatory prodrugs and methods of use thereof | 🖼🧊📄§ | 2026-03-17 | 2040-09-24 | 0 | 31 |
| 12576152 | Topical composition | 🖼🧊📄§ | 2026-03-17 | 2045-06-27 | 0 | 31 |
| 12576160 | Bispecific nanoparticle systems for targeting cancer cells | 🖼🧊📄§ | 2026-03-17 | 2042-05-06 | 0 | 31 |
| 12576157 | Peptide saporin conjugate for the treatment of cancer | 🖼🧊📄§ | 2026-03-17 | 2043-07-14 | 0 | 31 |
| 12576156 | Compound comprising self-immolative group and ligand-drug conjugate comprising same | 🖼🧊📄§ | 2026-03-17 | 2044-11-22 | 0 | 31 |